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Recently, it was reported that the product of Birt–Hogg–Dubé syndrome gene (folliculin, FLCN) is
directly phosphorylated by 50-AMP-activated protein kinase (AMPK). In this study, we identiﬁed ser-
ine 62 (Ser62) as a phosphorylation site in FLCN and generated an anti-phospho-Ser62-FLCN anti-
body. Our analysis suggests that Ser62 phosphorylation is indirectly up-regulated by AMPK and
that another residue is directly phosphorylated by AMPK. By binding with FLCN-interacting proteins
(FNIP1 and FNIP2/FNIPL), Ser62 phosphorylation is increased. A phospho-mimic mutation at Ser62
enhanced the formation of the FLCN–AMPK complex. These results suggest that function(s) of
FLCN–AMPK–FNIP complex is regulated by Ser62 phosphorylation.
Structured summary:
MINT-7298145, MINT-7298166: Flcn (uniprotkb:Q76JQ2) physically interacts (MI:0915) with AMPK alpha
1 (uniprotkb:P54645) by anti tag coimmunoprecipitation (MI:0007)
MINT-7298267: AMPK alpha 1 (uniprotkb:Q13131) phosphorylates (MI:0217) tsc2 (uniprotkb:P49816) by
protein kinase assay (MI:0424)
MINT-7298182: FNIP1 (uniprotkb:Q8TF40) physically interacts (MI:0915) with Flcn (uniprotkb:Q76JQ2)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7298132: AMPK alpha 1 (uniprotkb:Q13131) phosphorylates (MI:0217) Flcn (uniprotkb:Q76JQ2) by
protein kinase assay (MI:0424)
MINT-7298229: FNIPL (uniprotkb:Q9P278) physically interacts (MI:0915) with Flcn (uniprotkb:Q76JQ2)
by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Birt–Hogg–Dubé syndrome (BHDS) is an autosomal dominantly
inherited syndrome and is characterized by the development of
skin ﬁbrofolliculomas and spontaneous pneumothorax, in addition
to kidney cancers with chromophobic or oncocytic features [1]. The
responsible gene for BHDS (BHD) is a tumor suppressor and haschemical Societies. Published by E
inase; FLCN, folliculin; FNIP,
f Pathology and Oncology,
go, Bunkyo-Ku, Tokyo 113-been identiﬁed by positional cloning [2]. We identiﬁed a germline
mutation of the BHD homologue (Bhd) in the Nihon rat model of
hereditary renal carcinoma [3].
To better understand the molecular mechanism of tumorigene-
sis caused by BHD/Bhd-deﬁciency, it is necessary to elucidate the
function of BHD product (folliculin, FLCN). However, the physiolog-
ical activity of FLCN has not yet been determined. Baba et al. iden-
tiﬁed an FLCN-binding protein, FNIP1, and demonstrated that FLCN
is phosphorylated [4]. They also reported that FNIP1 binds 50-AMP-
activated protein kinase (AMPK), and that both FLCN and FNIP1 are
phosphorylated by AMPK [4]. Phosphorylations of FLCN were inﬂu-
enced by treatment with an AMPK inhibitor, as well as rapamycin
or by amino acid deprivation [4]. Our group and Hasumi et al. iden-
tiﬁed the second FLCN-binding protein, FNIP2/FNIPL, which islsevier B.V. All rights reserved.
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expression inﬂuenced the signaling pathway regulated by mam-
malian target of rapamycin kinase (mTOR), probably in a con-
text-dependent manner [4–6]. From these observations, it has
been suggested that FLCN is involved in energy and nutrient sens-
ing through the AMPK and mTOR signaling pathways [4].
The rapamycin-sensitive function of mTOR is negatively regu-
lated by AMPK and tuberous sclerosis tumor suppressor gene prod-
ucts (hamartin and tuberin) [7]. From the study of yeast mutants of
the BHD homologue, opposite roles of FLCN and tuberin in TOR sig-
naling have been suggested [8]. Thus, there may be a complex net-
work of tumor suppressors involved in the regulation of mTOR.
Detailed characterization of FLCN phosphorylation will provide
important information that might allow us to clarify the function
of FLCN in such a network.
In this study, we found that serine 62 (S62) is a major phosphor-
ylation site on rat FLCN, and report on the production of an anti-
phosphorylated FLCN antibody, which will be useful for the charac-
terization of FLCN.2. Materials and methods
2.1. General methods
For general methods (plasmid construction, cell culture,
transfection, immunoblot analysis and immunoprecipitation), see
Supplementary materials and methods.
2.2. Phosphatase treatment and metabolic labeling
Protein A/G beads (Calbiochem) with immunocomplex were
washed three times with 0.5% Tween 20/Tris-buffered saline
(TBST), then washed once with the buffer for calf intestinal alkaline
phosphatase (CIAP, Takara). Beads were resuspended in 100 ll of
CIAP buffer and treated with CIAP (80 units) for 20 min and then
washed three times with TBST and subjected to further analysis.
For metabolic labeling, Cos7 cells were transfected with plasmids
for Flag-tagged proteins. After 48 h of culture, the medium was
changed to phosphate-free DMEM (Gibco) supplemented with
10% dialyzed FBS (Gibco) and cells were incubated for 30 min.
Then, 32P-orthophosphate (GE Healthcare) was added to the med-
ium (0.1 mCi/ml) and cells were labeled for 4 h and lysed for
immunoprecipitation with anti-Flag antibody to detect 32P
incorporation.
2.3. Mass spectrometric analysis
Cos7 cells expressing FLCN-GST were lysed on ice in NP40 lysis
buffer [6]. The lysate was mixed with Glutathione-Sepharose 4B
beads (GE Healthcare) overnight at 4 C and bound proteins were
separated by a 10% SDS–PAGE and then visualized by silver stain-
ing. The FLCN bands were in-gel digested as previously described
[9]. The tryptic peptides were extracted, the solvent was evapo-
rated, and the peptides were redissolved in 10 ll of 1% formic acid.
Mass spectrometry was performed using API-QSTAR pulsar i (Ap-
plied Biosystems) with a nanoliquid chromatograph (DiNa; KYA
TECH Corporation) equipped with a 0.2 mm ID  50 mm Magic
C18 column. Amino acid sequences of the tryptic peptides were
determined by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS).
2.4. Antibodies
Anti-phospho-FLCN (S62) was generated by immunizing rabbits
with S62-phosphorylated peptide corresponding to aa 59–68(Arg-Ala-His-Ser-Pro-Ala-Glu-Gly-Ala-Ser) of rat FLCN with ami-
no-terminal cysteine for conjugation with haemocyanine (IBL).
Antibodies were puriﬁed by antigen-afﬁnity chromatography
(IBL). For other antibodies, see the Supplementary materials and
methods.
2.5. In vitro kinase assays
Cos7 cells expressing GST-tagged proteins were lysed on ice in
NP40 lysis buffer. The proteins were puriﬁed with Glutathione-Se-
pharose 4B beads and treated with CIAP as described above and
then the beads were incubated with or without active AMPKa1
subunit (Cell Signaling) in a solution containing 60 mM HEPES–
NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 0.5 lg/ll
PEG20.000, 100 lM ATP and 1 lCi/ll c32P-ATP (NEG002A; Perkin
Elmer) at 30 C for 20 min. The samples were subjected to SDS–
PAGE and transferred to the nylon membrane, and then incorpora-
tion of 32P was examined by autoradiography. In another system,
in vitro kinase assay for AMPKa1 was performed using His-FLCN
fragments as substrates. Proteins on nylon membrane were
visualized by immunoblot with alkaline phosphatase conjugated
secondary antibodies using the substrate, nitro-blue-tetrazolium
and 5-bromo-4-chloro-3-indolylphosphate (WAKO).3. Results and discussion
3.1. Ser62 is a phosphorylation site in FLCN
During a previous study, which we conducted for the identiﬁca-
tion of the Bhd germline mutation, we observed that rat FLCN mi-
grated as multiple bands in immunoblot analysis [4]. By using
deletion mutants and metabolic labeling, it was suggested that
the migration of FLCN was affected by phosphorylation in the ami-
no-terminal region and that rat FLCN has multiple phosphorylation
sites (Supplementary Fig. S1).
To identify the phosphorylation site in the amino-terminal re-
gion, we employed site-directed mutagenesis for candidate resi-
dues and examined its effects on the mobility of amino-terminal
fragment (DC-ter) in immunoblots after transient expression in
Cos7 cells. Among the mutations introduced, only the Ser62
(S62)-to-alanine (S62A) mutation completely eliminated slower
migrated bands in DC-ter (Fig. 1A and data not shown). It did not
completely abolish 32P-incorporation in metabolic labeling, sug-
gesting that other phosphorylation sites are present (Fig. 1A). Next,
we searched for phosphorylation sites in the transiently expressed
full-length FLCN–GST fusion protein by tandemmass spectrometry
and a peptide phosphorylated at S62 was identiﬁed (Fig. 1B). In this
analysis, no other phospho-peptide was detected.
To further analyze the FLCN phosphorylation at S62, we pre-
pared a rabbit polyclonal antibody (BHD-P1) speciﬁc for the phos-
pho-S62-containing FLCN peptide. We ﬁrst found that BHD-P1
efﬁciently reacted with transiently expressed wild-type but not
S62A mutant FLCN, in an upper band-speciﬁc manner (Fig. 1C).
The reactivity of BHD-P1 was completely blocked by pre-treatment
of antibody with phosphorylated antigen peptides, but not with
control unphosphorylated peptides (Supplementary Fig. S2A). In
addition, the reactivity of BHD-P1 was totally abolished by pre-
treatment of FLCN with alkaline phosphatase (Supplementary
Fig. S2B). These results suggested that BHD-P1 recognizes FLCN
phosphorylated at S62. We tested and found the reactivity of
BHD-P1 to endogenous FLCN from human, mouse and rat cell lines
(Supplementary Fig. S2C and data not shown). Taking these results
together, we concluded that FLCN is phosphorylated at S62 in vivo.
S62 and its surrounding region are conserved in terrestrial ani-
mal-speciﬁc manner (data not shown). As BHDS develops renal
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Fig. 1. Serine 62 (S62) is a phosphorylation site in FLCN. (A) Immunoblot and metabolic label analysis of site-directed mutants. Flag-tagged amino-terminal fragment of wild-
type (WT) and mutant (S38A, S55A, and S62A) FLCNs, expressed in Cos7 cells, were detected by immunoblotting with anti-Flag antibody (upper panel). Arrows indicate two
major bands of wild-type FLCN. 32P-incorporation was detected by autoradiography after immunoprecipitation with anti-Flag antibody (lower panel). Note that the upper
band was not detected and that the total intensity was diminished in the S62A mutant. (B) Mass spectrometry. Left and right panels show LC-ESI-MS/MS spectra of peptides
containing non-phosphorylated and phosphorylated S62, respectively. (C) Immunoblot analysis with phospho-S62-speciﬁc antibody. Flag-tagged wild-type (WT) and S62A
mutant (S62A) FLCN were immunoprecipitated with anti-Flag antibody from Cos7 cells and detected with phospho-S62-speciﬁc anti-FLCN (BHD-P1; upper panel) or anti-Flag
(lower panel) antibody. Arrows and arrowheads indicate the position of the upper and lower of two major bands detected by anti-Flag. Note that BHD-P1 recognizes the
upper band but not the lower band.
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terms of the species-speciﬁc as well as the tissue (respiratory or re-
nal)-speciﬁc regulation of FLCN function.
3.2. Ser62 of FLCN is phosphorylated in the AMPK-related pathway,
but is not a direct target of AMPK
We have detected an increase in the amount of slowly migrated
bands of FLCN after co-expressionwitha1-subunit of AMPK, aswell
as several other kinases (Fig. 2A and B, and data not shown). Accord-
ingly, the reactivity of FLCN protein with BHD-P1 was increased by
co-expression of AMPKa1. This reactivity was partially reduced in
FLCN from cells treated with an AMPK inhibitor (Compound C),
but not with rapamycin, suggesting that the regulatory pathways
for FLCN phosphorylation at S62 involve AMPK (Fig. 2A and B).
To determine whether S62 is directly phosphorylated by AMPK,
we performed in vitro kinase assays in two different systems. Both
wild-type and S62A mutant Flag–FLCN–GST fusion proteins, puri-
ﬁed from Cos7 cells were labeled with 32P by incubation with
AMPK in vitro (Fig. 2D). Thus, the short amino-terminal and car-
boxy-terminal GST fusion may not perturb phosphorylation by
AMPK. When deletion mutants were analyzed, ones covering resi-
dues from 293 to 356 were efﬁciently labeled (Fig. 2E). Consistent
with these results, the bacterially-expressed fragments covering aa
293–356 of FLCN were phosphorylated whereas the amino-termi-
nal region (aa 1–289) containing S62 was not (Supplementary
Fig. S3). These data suggest that S62 of FLCN is not directly phos-
phorylated by AMPK.
As S62 is embedded in the consensus phosphorylation sequence
for members of the AGC family kinase (R-X-R-X-X-S/T, where X
means any residue) and is followed by a proline, some member(s)of the AGC family or proline-directed protein kinases might phos-
phorylate FLCN at S62 [10]. So far, we have not detected efﬁcient
kinase activities using S6K1, Akt, RSK1 or Sgk1 by in vitro kinase
assay against FLCN [11]. Identiﬁcation of the kinase responsible
for S62 phosphorylation will clarify the complex relationship be-
tween AMPK-related pathways and the function of FLCN.
3.3. Ser62 phosphorylation of FLCN is induced by interaction with FNIP
proteins and may affect the formation of a complex with AMPK
To elucidate the functional signiﬁcance of S62 phosphorylation,
we tested the activity of S62 mutant FLCN to form a complex with
AMPK, FNIP1 and FNIP2/FNIPL [4–6]. When co-expressed with
FNIP proteins, wild-type FLCN showed an increase in the amount
of S62-phosphorylated form, consistent with previously reported
results [4–6]. This suggests that phosphorylation at S62 is induced
or stabilized by FNIP proteins. The increase in S62 phosphorylation
by FNIP proteins was suppressed by Compound C, but not by rap-
amycin, suggesting that it is exerted by an AMPK-dependent mech-
anism (Fig. 3A). In the co-immunoprecipitation assay, both S62A
and a phosphorylation-mimic serine-to-aspartic acid (S62D) mu-
tants exhibited no signiﬁcant change in the ability to bind FNIP
proteins (Supplementary Fig. S4). Although the formation of a com-
plex between FLCN and AMPKa1 was reported to be FNIP1-depen-
dent, we detected their interaction in transient co-expression
without FNIP1 expression (Fig. 3B). In the co-immunoprecipitation
assay, the S62D mutant exhibited increased binding activity with
AMPKa1 whereas the S62A mutant showed slightly reduced one
compared with wild-type FLCN (Fig. 3B). These results suggest that
FLCN phosphorylation at S62 may enhance or stabilize the
formation of a complex in which AMPKa1 and FLCN are involved.
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Fig. 2. S62 of FLCN is phosphorylated in the AMPK-related pathway, but may not be a direct target of AMPK. (A and B) Effects of rapamycin (A) and Compound C (B) on AMPK-
induced S62 phosphorylation. Flag-FLCN was transiently expressed with or without Myc-AMPK in Cos7 cells. After 24 h, rapamycin (20 nM; Rapa in A), Compound C (30 lM;
Comp C in B) or vehicle (DMSO) was added and cells were treated with drugs for 24 h. Immunoblottings were performed with the indicated antibodies: S6K, phospho-S6K;
ACC, phospho-ACC. (C–E) In vitro kinase assay for AMPK using transiently expressed FLCN in mammalian cells. Recombinant proteins are schematically depicted in (C). Wild-
type FLCN–GST (WT in D and E), full-length S62A mutant (S62A in D) and deletion mutants (aa numbers in E) were assayed. Upper panels show protein detection by anti-GST
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(A) Effects of FNIP1 or FNIP2/FNIPL expression on S62 phosphorylation. Cos7 cells
were transiently expressed with wild-type Flag-FLCN alone, or together with either
Myc-FNIP1 (FNIP1) or Myc-FNIP2/FNIPL (FNIPL). Cells were treated with rapamycin
(Rapa), Compound C (Comp C) or vehicle () for 24 h. The cell lysates were analyzed
by immunoblotting with indicated antibodies. (B) Binding of mutant FLCNs with
AMPKa1 subunit. Myc-AMPKa1 was transiently expressed in Cos7 cells with or
without () Flag-tagged wild-type (WT), S62A or S62D mutant FLCN. 48 h later, cell
lysates were subjected to immunoprecipitation with anti-Flag antibody. Total
lysates (Input) and immunoprecipitates (IP) were analyzed by immunoblotting
with indicated anti-tag antibodies.
42 L. Wang et al. / FEBS Letters 584 (2010) 39–43Overall, the binding of FLCN with FNIP proteins may increase the
FLCN–AMPKa1 complex via S62 phosphorylation. This may upreg-
ulate the direct phosphorylation of FLCN by AMPKa1 at residue(s)
other than S62.
There may be complex mechanisms for FLCN phosphorylation
in the AMPK and mTOR-related pathways. Phosphorylated FLCN-
speciﬁc antibodies, such as BHD-P1, which were generated in this
study, will be powerful tools for future studies. To unravel the
molecular mechanism of tumorigenesis associated with BHDmuta-
tion, understanding of FLCN function is necessary. Further studies
on the regulatory mechanism of FLCN phosphorylation will provide
many important clues.
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